UroGen Pharma Ltd’s filing revealed that its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $11236.0 on Sep 09 ’24. In the deal valued at $13.08 per share,859 shares were sold. As a result of this transaction, Schoenberg Mark now holds 145,091 shares worth roughly $1.86 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Smith Jason Drew sold 1,521 shares, generating $19,895 in total proceeds. Upon selling the shares at $13.08, the General Counsel now owns 25,226 shares.
Before that, Schoenberg Mark bought 859 shares. UroGen Pharma Ltd shares valued at $11,365 were divested by the Officer at a price of $13.23 per share.
Guggenheim initiated its UroGen Pharma Ltd [URGN] rating to a Buy in a research note published on August 22, 2024; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who decreased its forecast for the stock in early February from “a Buy” to “a Hold”. Berenberg began covering URGN with “Buy” recommendation on April 27, 2022. H.C. Wainwright maintained its rating on April 16, 2020. It rated URGN as “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock fall -2.73% to $12.84. Over the last five days, the stock has lost -4.32%. UroGen Pharma Ltd shares have fallen nearly -14.40% since the year began. Nevertheless, the stocks have fallen -19.30% over the past one year. While a 52-week high of $20.70 was reached on 06/14/24, a 52-week low of $10.60 was recorded on 05/13/24. SMA at 50 days reached $15.07, while 200 days put it at $15.15.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 12.63, which if violated will result in even more drops to 12.42. On the upside, there is a resistance level at 13.23. A further resistance level may holdings at 13.62. The Relative Strength Index (RSI) on the 14-day chart is 34.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.15%. Stochastics %K at 14.09% indicates the stock is a buying.
How much short interest is there in UroGen Pharma Ltd?
A steep rise in short interest was recorded in UroGen Pharma Ltd stocks on 2024-08-30, growing by 0.34 million shares to a total of 6.44 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 6.1 million shares. There was a rise of 5.34%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 13, 2020 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $53.
